PBAC backs ‘a’ flagging for etanercept biosimilar

The Pharmaceutical Benefits Advisory Committee has recommended the ‘a’ listing of etanercept biosimilar Brenzys, meaning that pharmacists will be able to substitute it for its competitor Enbrel.

The PBAC said its recommendation took account of clinical trial results showing the drug’s equivalent efficacy and safety with Enbrel in a number of settings, including in treatment-naïve patients and in one-way switches from Enbrel to Brenzys.